A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)

This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s) within the past year due to non-response or intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each attack; one attack will be treated with one tablet of the Combination Product (sumatriptan succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover design). [Study 2 of 2]

本研究为一项随机、双盲、安慰剂对照、交叉设计的门诊早期干预评估试验，纳入过去1年内因应答不佳或不耐受而停用短效曲普坦类（short acting triptan）药物的伴或不伴先兆偏头痛受试者。受试者需在每次偏头痛发作的轻度阶段完成两次独立发作的治疗：其中一次发作采用复方制剂（琥珀酸舒马普坦与萘普生钠，sumatriptan succinate and naproxen sodium）一片治疗，另一次发作采用安慰剂一片治疗（采用交叉设计）。【本研究为两项研究中的第二项】